News from ptc therapeutics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

May 20, 2022, 08:08 ET PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Upstaza™ (eladocagene exuparvovec; PTC-AADC) received a positive opinion from the...

May 18, 2022, 10:58 ET PTC anuncia atualização do rótulo do Translarna™ no Brasil para pacientes não ambulatoriais com distrofia muscular de Duchenne com mutação do tipo nonsense

May 18, 2022, 10:55 ET PTC anuncia la actualización de la marca Translarna™ en Brasil para pacientes no ambulatorios con mutación sin sentido de la distrofia muscular de Duchenne

Apr 08, 2022, 16:23 ET PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 8, 2022, the company approved non-statutory stock options to purchase an...

Mar 11, 2022, 08:00 ET PTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present three posters outlining data for EMFLAZA™ (deflazacort) in...

Feb 23, 2022, 08:00 ET PTC Therapeutics to Participate at Upcoming Investor Conferences

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Cowen Virtual 42nd...

Jan 26, 2022, 13:31 ET FDA concede análise prioritária ao Evrysdi® com base nos resultados do tratamento de bebês pré-sintomáticos com atrofia muscular espinhal

Jan 26, 2022, 11:36 ET La FDA otorga una revisión proritaria a Evrysdi® con base en los resultados del tratamiento de lactantes presintomáticos con atrofia muscular espinal

Jan 25, 2022, 01:00 ET FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental...

Jan 18, 2022, 08:00 ET PTC Therapeutics Announces Launch of 8th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the eighth annual STRIVE™ awards program for Duchenne muscular dystrophy...

Jan 18, 2022, 08:00 ET PTC Therapeutics anuncia el lanzamiento del octavo programa anual de premios STRIVE™ para financiar iniciativas que beneficien a la comunidad de la distrofia muscular de Duchenne

Jan 18, 2022, 08:00 ET PTC Therapeutics annonce le lancement du 8e programme annuel de prix STRIVE™ pour financer des initiatives au profit de la communauté de la dystrophie musculaire de Duchenne

Jan 18, 2022, 08:00 ET PTC Therapeutics anuncia los premios STRIVE™ para financiar iniciativas de distrofia muscular de Duchenne

Jan 18, 2022, 08:00 ET PTC Therapeutics anuncia lançamento do 8º programa anual de premiação STRIVE™ para financiar iniciativas que beneficiam a comunidade com distrofia muscular de Duchenne

Jan 18, 2022, 08:00 ET PTC Therapeutics gibt den Start des 8. jährlichen STRIVE™-Preisprogramms zur Finanzierung von Initiativen zugunsten der Duchenne-Muskeldystrophie-Gemeinschaft bekannt

Jan 13, 2022, 16:30 ET PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 7, 2022, the company approved non-statutory stock options to purchase an aggregate ...

Jan 13, 2022, 15:53 ET PTC Therapeutics annonce le lancement du 2022 Global Talent Pipeline Program

Jan 13, 2022, 13:43 ET PTC Therapeutics anuncia lançamento do programa Global Talent Pipeline de 2022